MimiX Biotherapeutics

MimiX Biotherapeutics is a startup developing sound-induced bioprinting technology. Its patented FastSkin tissue technology combines micrografts (tiny biological tissue entities obtained from healthy skin biopsies) with its proprietary Sound-Induced Morphogenesis (SIM) technology to improve wound care management. The company’s FastSkin product addresses unmet clinical needs in oncology and chronic wound treatment. Despite still being in the process of obtaining necessary U.S. market approvals, MimiX believes FastSkin can offer new therapeutic opportunities for treating complex wounds that are difficult to manage with conventional treatments.